PERTUZUMAB
Information current as at: 1 March 2026
The pharmaceutical company has not advised whether they intend to proceed or not within 60 days of receiving the ratified PBAC minutes. The process for listing is considered inactive.
Submission Details
- Brand name:
-
- Perjeta®
- Pharmaceutical company:
- ROCHE PRODUCTS PTY LTD
- Condition/indication:
(therapeutic use) -
- Human epidermal growth factor receptor 2-positive (HER2+) locally advanced, inflammatory or early stage breast cancer
- PBAC Submission type:
- Change to existing listing (Standard Re-entry Pathway)
- Comment:
- --
- Public Summary Document:
- PBAC Public Summary Documents – March 2025
- Related medicines:
Progress Details
-
Submission received for: - March 2025 PBAC meeting
-
Opportunity for consumer comment: - Open 27/11/2024 and close 29/01/2025 (see PBS Website)
-
PBAC meeting: - Held on 12/03/2025
-
PBAC outcome published: - Recommended (see PBAC Outcomes)
-
Notice of intent submitted:
- Awaiting lodgement from pharmaceutical company
-
5Lodgement of required documentation:
- Has not yet commenced
-
6Agreement to listing arrangements:
- Has not yet commenced
-
7Government processes:
- Has not yet commenced
-
8Medicine listed on the PBS:
- Has not yet occurred
Case ID: a1015
Page last updated: 30 November 2025